In our previous blog, we outlined the core categories of class actions where MCAG focuses its filing and recovery efforts. As we head into 2026, this follow-up highlights the specific cases within those categories  that continue to warrant close attention. Our Research team reviews daily federal docket activity and tracks cases throughout their lifecycle. We focus on matters that show real momentum, affect broad segments of industry, and have practical relevance for our clien

As we close out the year, it’s a good moment to step back and take stock of the class action landscape—and, just as importantly, to reaffirm where MCAG focuses its efforts on behalf of our clients. Each year brings a steady stream of new settlements, court rulings, and headline-grabbing cases. But not every class action represents a meaningful or appropriate recovery opportunity for organizations. At MCAG, our role is not to chase volume—it is to apply experience, judgment, a

Merchants may be eligible for additional recoveries beyond the Visa Mastercard and Discover Merchant Settlements. As the payments industry evolves, more class-action settlements are emerging for merchants, including those who absorbed fraud losses due to EMV liability shifting. When EMV chip cards rolled out in 2015, liability for fraudulent transactions shifted to merchants that didn’t use EVM-compliant terminals. Studies show fraud loss rates for non-EMV transactions rose f

Why It Matters For years, the skyrocketing price of insulin has been at the forefront of America’s healthcare debate, and now it’s at the center of one of the most significant pharmaceutical pricing cases in history. The ongoing Insulin Pricing Multidistrict Litigation (MDL No. 3080) consolidates lawsuits against the nation’s three largest insulin manufacturers and three major pharmacy benefit managers (PBMs), who together control roughly 80% of the U.S. prescription drug ma